Skip to content

Role of ShengJingSan in treatment of Asthenospermia via activation of sperm-specific catsper ion channel

Role of ShengJingSan in treatment of Asthenospermia via activation of sperm-specific catsper ion channel

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001765
Enrollment
Unknown
Registered
2011-12-03
Start date
2011-01-05
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthenospermia

Interventions

1:administration Sheng Jing San
2:administration Levocarnitine
3:administration placebo

Sponsors

Neuroscience Research Instituteand Department of Neurobiology, Peking University, Beijing China
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Conforming to the diagnosis of traditional Chinese Medicine of male sterility and diagnosis standard of western medicine of weak sperm; 2. Age from 20 to 40; 3. Whose main reason of male sterility is weak sperm; 4. Medical history over one year; 5. Those who are informed.

Exclusion criteria

Exclusion criteria: 1. Clearly primary weak sperm, or secondary organic weak sperm (shaft, chromosomal abnormalities); 2. The patient can not be safely continued treated; 3. The patient has a medical history of some other serious familial hereditary disease in the recent six months, such as leukemia, hemophilia and so on; 4. Combined with serious diseases of other systems, such as decompensated heart failure, severe liver function damage (serum transaminase >=2*medical reference value upper limit, creatinine clearance rate<=40 ml/min or nephropathy in active stage); 5. Allergic constitution, surely or possibly allergy to chinese herbal medicine (including previous chinese herbal decoction or those makes people become palpitations, facial flushing,headache, hypotension, edema of lower extremity and other adverse reactions); 6. Already having bleeding tendency or bleeding disease, or coagulation disorders out of control, or active bleeding in two weeks and treatment of invasive operation, or severe trauma or operation history in twelve weeks; 7. Seriously primary diseases and mental disease influential to life, or those who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
sperm concentration;Sperm motility;Sperm morphology;Seminal plasma biochemistry;The expression of the CatSper channel protein;

Countries

China

Contacts

Public ContactXING Guo-gang
ggxing@bjmu.edu.cn+86 010 82801067

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026